Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Efficacy and safety of coenzyme Q10 supplement on simvastatin induced myalgia and transaminase increment

View through CrossRef
Objective To investigate whether Coenzyme Q10 (CoQ10) supplement can help ease or eliminate some of the side effects that result from taking simvastatin medication in coronary artery disease (CAD) patients with hypercholesterolemia. These side effects include myalgia, fatigue and Transaminase Increment. Methods 198 CAD patients with hypercholesterolemia were randomised to CoQ10 (30 mg/day) plus simvastatin (40 mg/day) as therapy group (n=99) or placebo plus simvastatin (40 mg/day) as control group (n=99). The incidence of myalgia and fatigue in the two groups were compared in 3 months after treatment. Plasma CoQ10 level, creatine kinase (CK), transaminase (ALT, AST) and blood lipids (TC, TG, LDL-C, HDL-C) were measured at baseline, 1 month and 3 months after treatment. Results The incidence of myalgia and fatigue demonstrated a decrease in therapy group compared with control group (3% vs 12%, p<0.01). Plasma CoQ10 level was no significant difference in therapy group in 1 month and 3 months after treatment, but in the control group, there was obviously decreased in both 1 month and 3 months after treatment compared with baseline (0.43±0.16 vs 0.51±0.13, 0.39±0.14 vs 0.51±0.13, p<0.05). CK, ALT and AST of pre and post therapy had no significant difference in therapy group (p>0.05), but in control group CK, ALT and AST were all increased significantly in 3 months compared with baseline. TC, TG and LDL-C were decreased significantly (p<0.01) both in therapy and control group post-therapy. Conclusion Simvastatin causes a marked decrease in plasma CoQ10 level in CAD patients. CoQ10 supplement can reduce myalgia and fatigue occurrence, decrease transaminase and creatine kinase increase caused by simvastatin. These data suggest that simvastatin related myopathy is associated with decrease in blood CoQ10 level. Widespread inhibition of CoQ10 synthesis could explain the most commonly reported adverse effects of simvastatins, especially myalgia, fatigue and rhabdomyolysis. So the combination of CoQ10 and simvastatins is safe and effective in CAD patients complicated by hypercholesterolemia.
Title: Efficacy and safety of coenzyme Q10 supplement on simvastatin induced myalgia and transaminase increment
Description:
Objective To investigate whether Coenzyme Q10 (CoQ10) supplement can help ease or eliminate some of the side effects that result from taking simvastatin medication in coronary artery disease (CAD) patients with hypercholesterolemia.
These side effects include myalgia, fatigue and Transaminase Increment.
Methods 198 CAD patients with hypercholesterolemia were randomised to CoQ10 (30 mg/day) plus simvastatin (40 mg/day) as therapy group (n=99) or placebo plus simvastatin (40 mg/day) as control group (n=99).
The incidence of myalgia and fatigue in the two groups were compared in 3 months after treatment.
Plasma CoQ10 level, creatine kinase (CK), transaminase (ALT, AST) and blood lipids (TC, TG, LDL-C, HDL-C) were measured at baseline, 1 month and 3 months after treatment.
Results The incidence of myalgia and fatigue demonstrated a decrease in therapy group compared with control group (3% vs 12%, p<0.
01).
Plasma CoQ10 level was no significant difference in therapy group in 1 month and 3 months after treatment, but in the control group, there was obviously decreased in both 1 month and 3 months after treatment compared with baseline (0.
43±0.
16 vs 0.
51±0.
13, 0.
39±0.
14 vs 0.
51±0.
13, p<0.
05).
CK, ALT and AST of pre and post therapy had no significant difference in therapy group (p>0.
05), but in control group CK, ALT and AST were all increased significantly in 3 months compared with baseline.
TC, TG and LDL-C were decreased significantly (p<0.
01) both in therapy and control group post-therapy.
Conclusion Simvastatin causes a marked decrease in plasma CoQ10 level in CAD patients.
CoQ10 supplement can reduce myalgia and fatigue occurrence, decrease transaminase and creatine kinase increase caused by simvastatin.
These data suggest that simvastatin related myopathy is associated with decrease in blood CoQ10 level.
Widespread inhibition of CoQ10 synthesis could explain the most commonly reported adverse effects of simvastatins, especially myalgia, fatigue and rhabdomyolysis.
So the combination of CoQ10 and simvastatins is safe and effective in CAD patients complicated by hypercholesterolemia.

Related Results

Studi Literatur Pemanfaatan Koenzim Q10 sebagai Antioksidan
Studi Literatur Pemanfaatan Koenzim Q10 sebagai Antioksidan
Abstract. Coenzyme Q10 (CoQ10) is a lipophilic antioxidant that plays an important role in cellular energy metabolism and protection against oxidative stress. As we age and increas...
Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation
Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation
Background: Cisplatin is an anticancer drug used in the management of solid tumors, however, dose-related nephrotoxicity is one of its major problems. Agents having antioxidants, a...
Effect of Coenzyme Q10 Supplementation on Testosterone
Effect of Coenzyme Q10 Supplementation on Testosterone
Enhancing testosterone production in males is a continuous research direction for many scientists in the field, due to its role as a principal sex hormone and as a crucial modulato...
e0043 Effects of simvastatin on angiogenesis and the expression of Ang1 after myocardial infarction in rats
e0043 Effects of simvastatin on angiogenesis and the expression of Ang1 after myocardial infarction in rats
Objective To investigate the effects of simvastatin on myocardial angiogenesis and the expression of angiopoietin-1 after experimental myocardial infarction (MI) ...
e0044 The role of Ang1 and eNOS in the proangiogenic effect of simvastatin after myocardial infarction in rats
e0044 The role of Ang1 and eNOS in the proangiogenic effect of simvastatin after myocardial infarction in rats
Objective To investigate the roles of angiopoietin-1 (Ang-1) and endothelial nitric oxide synthase (eNOS) in pro-angiogenic effect of simvastatin after experiment...
GW24-e3967 Effects of simvastatin on vascular endothelial function in patients with coronary heart diseases
GW24-e3967 Effects of simvastatin on vascular endothelial function in patients with coronary heart diseases
Objectives To investigate the effects of simvastatin therapy on vascular endothelial function in patients with coronary heart diseases (CAD). ...
CRP as a marker of inflammation: Mitigation of Ulcerative Colitis in rats by Mesalazine and Coenzyme Q10.
CRP as a marker of inflammation: Mitigation of Ulcerative Colitis in rats by Mesalazine and Coenzyme Q10.
Background: Ulcerative colitis is a global health issue with no definitive treatment options available. Mesalazine is one of the first-line therapies available, and Coenzyme Q10 is...

Back to Top